Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Cash from Financing Activities (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Cash from Financing Activities for 7 consecutive years, with -$99.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities changed N/A to -$99.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $137.2 million, a N/A change, with the full-year FY2025 number at $137.2 million, down 35.61% from a year prior.
  • Cash from Financing Activities was -$99.9 million for Q4 2025 at Soleno Therapeutics, down from $218.2 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $218.2 million in Q3 2025 to a low of -$99.9 million in Q4 2025.